Predictions
Vertex Pharmaceuticals Inc.
Start price
Target price
Perf. (%)
€196.52
08.01.22
08.01.22
€915.00
14.01.27
14.01.27
122.70%
28.06.24
28.06.24
Could be very worthwhile Investment >20% year
Revenue growth > 30% per year expected
EBIT growth > 30% per year expected
ROE higher than 15% per year
Intuit Inc.
Start price
Target price
Perf. (%)
€603.90
19.11.21
19.11.21
€660.00
19.09.24
19.09.24
3.00%
28.06.24
28.06.24
Revenue growth >5% per year expected
ROE higher than 15% per year
EBIT growth >5% per year expected
Could be worthwhile Investment >10% per year
Apple Inc.
Start price
Target price
Perf. (%)
€136.02
17.11.21
17.11.21
€250.00
08.02.27
08.02.27
46.63%
28.06.24
28.06.24
Market Leader or Top 3
Well known brand
Very Future proof/growth oriented business model
Top Rating
Berkshire Hathaway Inc. B
Start price
Target price
Perf. (%)
€249.20
17.11.21
17.11.21
€420.00
17.11.26
17.11.26
52.45%
28.06.24
28.06.24
Top Rating
Very positive Cash Flow expected
Fair valuation
Very capable Management
O'Reilly Automotive Inc.
Start price
Target price
Perf. (%)
€554.20
10.11.21
10.11.21
€700.00
10.11.24
10.11.24
77.95%
28.06.24
28.06.24
Could be worthwhile Investment >10% per year
Medium risks for its business
Small cyclical dependencies
Future proof or reliable business model
Bank of America Corp.
Start price
Target price
Perf. (%)
€36.23
26.09.21
26.09.21
€50.00
26.09.24
26.09.24
8.84%
28.06.24
28.06.24
Intel Corp.
Start price
Target price
Perf. (%)
€49.51
26.02.21
26.02.21
€30.00
19.10.25
19.10.25
-35.21%
28.06.24
28.06.24
Innovative
Differentiated customer and product portfolio
Good culture
Well known brand
Oracle Corp.
Start price
Target price
Perf. (%)
€34.93
01.12.16
01.12.16
€145.00
08.09.26
08.09.26
299.94%
28.06.24
28.06.24
Revenue growth >5% per year expected
EBIT growth >5% per year expected
Undervalued
High dividend yield expected
Gilead Sciences Inc
Start price
Target price
Perf. (%)
€70.48
30.09.16
30.09.16
€98.00
08.09.26
08.09.26
16.13%
28.06.24
28.06.24
Could be very worthwhile Investment >20% year
Revenue growth >5% per year expected
EBIT growth >5% per year expected
Undervalued